指南与共识MDS 与骨髓增殖性肿瘤

CALR突变原发性血小板增多症管理的未满足临床需求:欧洲白血病网共识提案

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.
指南 / 共识 · Lancet Haematol · 2021-01-01

欧洲白血病网针对CALR突变原发性血小板增多症治疗不确定性,组建指导委员会和10人专家组,提出51项潜在未满足需求并评分。经两轮Delphi法达成共识,形成14条推荐和6项解决方案,涵盖低危患者抗血小板治疗、极端血小板增多定义与管理、降细胞治疗指征及妊娠管理等。

要点

  • 无症状、经典低危、无心血管危险因素的CALR突变ET患者可谨慎观察。
  • 低危有症状且血小板1000-1500×10^9/L者慎用抗血小板,可考虑降细胞治疗。
  • 极端血小板增多(>1500×10^9/L)推荐降细胞,年轻患者优选聚乙二醇干扰素α。

核心结论

  • 欧洲白血病网通过共识推荐用于CALR突变ET常规管理,并建议设计新临床研究。

研究设计与样本

  • 欧洲白血病网组建4人指导委员会和10人专家组,采用邮件两轮Delphi法达成共识。
  • 专家组提出51项潜在未满足临床需求并评分,共识定义为90%专家同意。

主要发现

  • 达成共识包括14条推荐和6项解决方案。
  • 关键推荐涉及低危患者抗血小板、极端血小板增多管理、降细胞指征及妊娠管理。

关键数值与推荐

  • 无症状、经典低危、无心血管危险因素的CALR突变ET患者推荐谨慎观察。
  • 低危有症状且血小板1000-1500×10^9/L者慎用抗血小板,降细胞治疗为合适选择,尤其合并获得性血管性血友病时。
  • 极端血小板增多(血小板>1500×10^9/L)推荐降细胞治疗,年轻患者优选聚乙二醇干扰素α。
  • 不适合聚乙二醇干扰素α者可选用羟基脲或阿那格雷。
  • 高危妊娠患者治疗流程不应根据基因型改变。

临床怎么用

  • 将共识推荐用于CALR突变ET的常规管理。
  • 对低危患者评估心血管危险因素和血小板水平以决定抗血小板或降细胞治疗。
  • 年轻极端血小板增多患者优先考虑聚乙二醇干扰素α。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recommendations regarding management of essential thrombocythaemia rely on studies done before the discovery of the CALR mutation. On May 20, 2020, the European LeukemiaNet annual meeting was held with the goal to identify unmet clinical needs in myeloproliferative neoplasms. Because patients with a CALR mutation have specific clinical characteristics, treatment of CALR-mutated essential thrombocythaemia was considered an unmet clinical need by the European LeukemiaNet. The elaboration of a consensus document with recommendations according to current evidence was proposed as a solution for resolving uncertainties in the treatment of CALR-mutated essential thrombocythaemia. A steering committee comprising four European LeukemiaNet members was then formed and a panel of ten experts in the field was recruited. The experts proposed 51 potential unmet clinical needs in the management of CALR-mutated essential thrombocythaemia and were asked to score the relevance of each topic. Those topics that obtained the highest scores as relevant unmet clinical needs were identified, including antiplatelet therapy in patients at low risk, definition of extreme thrombocytosis and its management in patients at low risk, indications of cytoreduction and targets of therapy, first-line treatment of choice in young patients (<60 years), and management of pregnancy. After the steering committee revised the available evidence for each topic, a consensus on management and proposal for improving knowledge was achieved by use of an email-based, two round, Delphi approach. Consensus was achieved when 90% of the panellists agreed with a statement and included 14 recommendations and six solution proposals. Key recommendations included careful observation for asymptomatic patients with classical, low-risk, CALR-mutated essential thrombocythaemia without cardiovascular risk factors; caution in the use of antiplatelet therapy for symptomatic patients at low risk with platelet counts of 1000-1500 × 109 platelets per L, in such cases cytoreduction is an adequate option, especially if adquired Von Willebrand disease is present; cytoreduction is recommended for extreme thrombocytosis (platelet count >1500 × 109 platelets per L) with pegylated interferon alfa being the preferred option for younger patients; both hydroxycarbamide and anagrelide might be given to patients ineligible for pegylated interferon alfa; and treatment algorithms for patients with high-risk pregnancies should not be changed according to genotype. The European LeukemiaNet proposes to use these recommendations in the routine management of patients with CALR-mutated essential thrombocythaemia, and designing new clinical studies in this field might be useful.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Alvarez-Larrán A, Sant'Antonio E, Harrison C, et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021. PMID: 34450103. doi:10.1016/S2352-3026(21)00204-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。